CD274 and neoplasm: For instance, investigating potential biomarkers—such as PD-L1 expression levels, tumor mutational burden, or immune cell infiltration within the tumor microenvironment—could help identify patient subgroups most likely to benefit from this regimen and elucidate potential mechanisms of resistance.